TB-6113 · REV C · Technical newsheet

Device profile

Biomatter Closes $18M Series A to Build Enzyme Design Facility

Biomatter's $18M Series A funds a 2,000 m² Vilnius facility opening in 2027, as the AI enzyme designer targets day-long turnaround for custom enzymes already shipping in Thermo Fisher products.

By Sophie Lindqvist3 min read621 words

Features

  • Biomatter raised an oversubscribed $18M Series A led by Astanor, with UVC Partners, Inventure and Metaplanet participating.
  • A 2,000 m² enzyme design and testing facility in Vilnius is scheduled to open in 2027.
  • The company has delivered over 50 custom enzymes to more than 25 enterprise customers, including AstraZeneca, BASF, Sanofi and Thermo Fisher partnerships.
  • Its technology features in Thermo Fisher's Invitrogen SuperScript V Reverse Transcriptase, enabling room-temperature storage for up to six months.
  • Current custom enzyme programs complete in weeks; the goal is days through automation and integrated testing.
Biomatter Raises $18 Million Series A Led by Astanor to Expand AI-Powered Enzyme Design
Device photoBiomatter Raises $18 Million Series A Led by Astanor to Expand AI-Powered Enzyme Design — leoleobobeo / pixabay

Biomatter has closed an oversubscribed $18 million Series A round, led by Astanor, with existing investors UVC Partners, Inventure and Metaplanet joining. The Lithuania-based company designs enzymes with generative AI, and it will spend a chunk of the money on a 2,000-square-meter (about 21,500-square-foot) design and testing facility in Vilnius, scheduled to open in 2027.

That facility matters for a practical reason: it pulls enzyme development and laboratory testing in-house. Today Biomatter completes custom enzyme design programs in weeks, against the months or years conventional development often takes. The stated target is to compress that timeline to days using expanded automation and integrated testing. The company will also grow its US commercial operation — roughly half of its customers sit there — and keep investing in its computational platform and proprietary enzyme dataset.

What's actually validated?

Biomatter, founded in 2018, doesn't modify naturally occurring enzymes. It designs new ones for specific chemical reactions, combining generative AI with experimentally generated biological data. Each design goes through experimental validation before delivery, and the results feed the proprietary dataset that improves subsequent designs — a closed loop between computation and wet lab.

The track record is concrete. More than 50 custom enzymes delivered to over 25 enterprise customers across Europe, the US and Japan, with named users including AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi and Tereos. Several of those relationships have grown into multi-year development programs, and the technology spans pharmaceutical, diagnostics, agriculture and industrial biotechnology applications.

Where the enzymes already ship

The clearest proof point is commercial, not preprint. Biomatter's technology sits inside Thermo Fisher Scientific's Invitrogen SuperScript V Reverse Transcriptase, an enzyme that converts RNA into DNA for molecular biology and mRNA research. Through that collaboration, Biomatter improved the enzyme's oxidation resistance, contributing to reagent stability that supports ambient shipping and room-temperature storage for up to six months.

A second example pushes past nature's catalogue. The company developed a methylase for mRNA vaccine manufacturing that works without S-adenosylmethionine (SAM), an additive that naturally occurring methylases require. It's a demonstration of designing enzymes for reactions — or at least reaction conditions — that biology hasn't supplied on its own.

The research foundation includes a 2021 publication in Nature Machine Intelligence showing generative models producing functional enzymes substantially different from natural ones.

What the investors said

CEO and co-founder Laurynas Karpus framed the ambition plainly: "Our goal is to make a custom enzyme as easy to order as a catalog product, including for reactions that don't have one today." He added that the funding round lets Biomatter "design enzymes from the chemistry up at a larger scale and get them into customers' products faster."

Oliver Schoppe, partner at UVC Partners, drew the line between Biomatter and the rest of the AI-biology field: "Most companies working on AI for biology are still proving it works. Biomatter's enzymes are already in products shipping from some of the largest manufacturers in Europe and the United States, which is why we increased our investment in this round."

Who's behind the money

Lead investor Astanor, founded in 2017, backs early- and growth-stage companies in agriculture, food production and human health, with roughly 50 investments across Europe, North America and other markets. UVC Partners manages more than €800 million and invests in European B2B technology, including AI-driven businesses.

Biomatter did not disclose its post-round valuation, the individual investor commitments, or total capital raised to date.

The open question for practitioners: if the Vilnius facility really cuts custom enzyme turnaround to days, does enzyme sourcing start to look more like ordering a catalog reagent than commissioning a development program?

via citybiz.co (Source)

Filed under

  • biomatter
  • enzyme-design
  • generative-ai
  • series
  • biotechnology
Share this article:

More from Sophie Lindqvist

Sophie Lindqvist

Show full bio

News editor covering regulation, policy and their impact on Instruments, test and measurement at Testbench Report.

110 articles

Application notes

« Previous articleNext article »